A 1-year randomised controlled trial of pharmacist-led collaborative care versus standard care in 400 adults with type 2 diabetes, reporting EQ-5D and visual analogue scale quality-of-life gains alongside a larger HbA1c reduction. PICO summary and expert commentary.
Browsing: Diabetes & Glycaemic Control
A small single-blind RCT testing whether a family-centered empowerment program improves patient-reported illness acceptance and self-management in type 2 diabetes. PICO summary and expert commentary.
In QWINT-3, once-weekly insulin efsitora alfa was non-inferior to once-daily degludec for HbA1c lowering in basal-insulin-treated type 2 diabetes, with comparable hypoglycaemia. PICO summary and expert commentary.
QWINT-4 phase 3 trial: once-weekly insulin efsitora alfa was non-inferior to daily glargine U100 for HbA1c in basal-prandial-treated type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the DIVERSITY-CVR trial tests whether baseline ALT predicts differential HbA1c and time-in-range responses to dapagliflozin versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
A small randomized crossover study in eight adults with type 1 diabetes on automated insulin delivery found that splitting isomaltulose into smaller servings during exercise produced steadier plasma glucose than a single pre-exercise serving. PICO summary and expert commentary.
A 12-week four-arm randomised trial in 36 male recreational athletes found that combined diet plus exercise improved body composition and glycaemic markers, with small effect sizes. PICO summary and expert commentary.
Once-weekly fixed-dose insulin efsitora was noninferior to once-daily glargine for HbA1c reduction over 52 weeks in insulin-naive type 2 diabetes, with less hypoglycaemia. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A randomized trial testing whether a patient previsit activation handout, added to physician academic detailing, increases diabetes medication deprescribing in adults 75 and older. PICO summary and expert commentary.